NanoBio Nasal Antiseptic Launch Accelerated As COVID-19 Spikes Demand For Personal Sanitizers
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.
You may also be interested in...
BlueWillow Biologics points to recent in vitro tests it conducted with Public Health England showing NanoBio Protect killed COVID-19 as additional support for using nasal antiseptics to help prevent infections from the novel coronavirus. The firm also will soon offer sales of NanoBio Protect on Amazon.
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
Eschewing the standard approval mechanisms for COVID-19 vaccines is likely only appropriate in very limited high-risk populations, unless clinical efficacy outcomes are available, former FDA leaders say.